How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,084 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients

by a qualified clinician for at least 1 monthly cycle prior to study drug administration. Medroxyprogesterone acetate (eg, Depo-Provera®) administered for a minimum of 1 monthly cycle prior to administration of the study drug and continuing through 1 month following study completion. Hysterectomy or surgical sterilization. Abstinence. Double barrier method (diaphragm with spermicidal gel or condoms with contraceptive foam). NOTE: For subjects prescribed Orkambi: Orkambi may substantially decrease hormonal

2017 Clinical Trials

182. Exercise Physiology Study

and HIPAA documents. Exclusion Criteria: Female of childbearing potential who is pregnant, intending to become pregnant, breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill/patch/vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Any cardiovascular disease, defined as clinically significant EKG abnormality at the time of screening

2017 Clinical Trials

183. A Clinical Trial to Evaluate the Effectiveness of Hairfinity on Improving Hair Health and Rate of Growth

patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Intrauterine devices Vasectomy of partner Double Barrier Method Non-heterosexual lifestyle Fitzpatrick skin type of I-V (See appendix 3) Willing to maintain the colour of and style of the hair cut for the duration of the study Willing to maintain shampooing frequency and general hair regime for the duration of the study Willing to not cut hair

2017 Clinical Trials

184. Targeted Microbiome Transplant in Atopic Dermatitis

pounds [95.5 Kg]); and Females of childbearing potential who are willing to use adequate contraception 30 days prior to the Screening Visit and until participation in the study is complete. --Females of childbearing potential must agree to use an acceptable method of birth control (e.g. total abstinence, oral contraceptives, intrauterine device (IUD), barrier method with spermicide, surgical sterilization or surgically sterilized partner, Depo-Provera, Norplant, NuvaRing, or hormonal implants

2017 Clinical Trials

185. Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)

are receiving an elemental diet or parenteral nutrition. Subjects who are treated with insulin. Women with childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or Depo-provera contraceptive, or barrier plus spermicide); pregnant or breastfeeding mothers. Subjects who will be unavailable for the duration of the trial, who are unlikely to be compliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason. Known sensitivity

2017 Clinical Trials

186. Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

barrier method and an acceptable hormonal method must be used. Acceptable barrier methods include condom (male or female) and a spermicide (cream, film, foam, or gel), diaphragm or cervical cap with spermicide, and the birth control sponge. Acceptable hormonal methods include birth control patch, shot (Depo-Provera), and pills, and the vaginal ring (NuvaRing). **Study vaccination or CHMI Women of childbearing potential must agree to continue use of a highly effective form of contraception through 90

2017 Clinical Trials

187. NMDA Receptor Modulation for Hyperarousal in PTSD

includes: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective IUD/IUS, Depo-Provera injections, oral contraceptive, and Evra Patch or Nuvaring. Women should be on a stable method of birth control for a minimum of 3 months , prior to randomization and 3 months after the last dose of IP. Women of non-childbearing potential. Women of non-childbearing potential are defined as women who are either permanently sterilized (hysterectomy

2017 Clinical Trials

188. Cognition and Smoking Relapse (HCS)

consent to use a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-Provera injection, contraceptive patch, tubal ligation) or abstain from sexual intercourse during the time they are in the study and using transdermal nicotine. Able to communicate fluently in English. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent/HIPAA form. Exclusion Criteria: Smoking Behavior

2017 Clinical Trials

189. A Study Evaluating Good Idea on Glucose Homeostasis in a Healthy Population

contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Intrauterine devices Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) Vasectomy of partner (shown successful as per appropriate follow-up) White North American (should include Hispanic, non-Hispanic, Aboriginal and Asian) or African American Stable body weight defined as no more than ± 3 kg change during the last 2 months Agree to maintain consistent

2017 Clinical Trials

190. Factors associated with contraceptive use in Tigray, North Ethiopia (PubMed)

among 1966 women of reproductive age group (15-49) in 13 districts (3 urban and 10 rural) from May-June 2015. Multistage sampling technique was employed to approach the study participants. Data were analyzed using SPSS version 20. Multiple variable logistic regression analysis was used to identify the effect of independent variables on utilization of contraceptive use.Out of total 1966 women, 1879 (95.6%) have ever heard about family planning. Depo-Provera (depot medroxyprogesterone acetate, or DMPA (...) ) was the most popular contractive method as mentioned by 1757 (93.5%) of the participants. The overall contraceptive prevalence rate among all women was 623 (35.6%) while the contraceptive prevalence rate among married women was 543 (41.0%). Seven-in-ten women had ever used short acting contraceptive. In fact Depo-Provera was the most common type of contraceptive used as mentioned by 402 (64.5%) of the women. The odds of using family planning by married women living in urban areas was two times more than

Full Text available with Trip Pro

2017 Reproductive health

191. Uptake of long-acting reversible contraceptive devices in Western region of The Gambia (PubMed)

based cross-sectional study of women attending family planning clinic were studied using intervieweradministered questionnaire which included information on socio-demographic factors, reproductive health and contraceptive use of the participants.About 89 % of study participants used long acting reversible contraceptive methods. Of the three commonly available long acting reversible contraceptive methods, Depo Provera was the most commonly used method; 78 of 141 (55.32%); followed by implants (43.3 (...) %) and intrauterine contraceptive (1.42%). Being housewives, with 3-4 living children and having secondary level education were associated with high uptake of LARC.The uptake of long acting reversible contraceptive was high; with Depo Provera as the most commonly used contraceptive method in The Gambia. There seemed to be an increase in the uptake of implants; with intrauterine contraceptive device being the least commonly used method.

Full Text available with Trip Pro

2017 African health sciences

192. Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection (PubMed)

Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection Depot medroxyprogesterone acetate (Depo-Provera) has been associated with an increased risk of HIV acquisition. In a longitudinal study, we investigated the impact of Depo-Provera use by healthy women on expression of immune markers for HIV preference and on HIV infection ex vivo at baseline (visit 1), one month (visit 2) and three (...) months (visit 3) after Depo-Provera treatment. We found a significant increase in the frequency and expression of integrin α4β7 on CD4+ T cells at visit 2. Interestingly, Hispanic but not black women exhibited a significant increase in integrin α4β7 cell numbers and expression levels at visit 2, whereas, black but not Hispanic women exhibited a significant change in CCR5 and CD38 expression levels between visit 2 and visit 3. The frequency of terminal effector memory CD4+ T cells decreased

Full Text available with Trip Pro

2017 ImmunoHorizons

193. Osteoporosis: Prevention and Treatment

. Medications with Risk for Bone Loss or Fracture Definite risk Immunosuppressants • Glucorticoids (systemic >> inhaled a , intranasal, topical, others) • Cyclosporine [Gengraf®, Neoral®, Sandimmune®] • Tacrolimus [Prograf®] • Mycophenolate mofetil [CellCept®] Hormonal and antihormonal agents • Medroxyprogesterone acetate [Depo-Provera®] b • Tamoxifen, before menopause • Aromatase inhibitors (anastrozole/Arimidex®, letrozole/Femara®) • GnRH analogs (leuprolide/Lupron®, goserelin/Zoladex®

2013 University of Michigan Health System

194. Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system

been accredited by NICE). The NICE guideline on Long-acting reversible contraception offers best-practice advice for all women of reproductive age who may wish to regulate their fertility by using copper intrauterine devices, progestogen-only intrauterine systems (Mirena) and progestogen-only injectable contraceptives (intramuscular depot medroxyprogesterone acetate, Depo-Provera and norethisterone enantate, Noristerat). The progestogen-only subdermal implant, Implanon, recommended in the guideline (...) be considered first-line £7.95 to £27.11 c Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 16 of 20Etonogestrel implant (Nexplanon) 68 mg subdermal implant for up to 3 years £79.46 a Intramuscular depot medroxyprogesterone acetate (Depo- Provera) 150 mg/ml intramuscular injection every 12 weeks (±5 days) £6.01 c Subcutaneous

2014 National Institute for Health and Clinical Excellence - Advice

195. Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA-SC)

2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary A new formulation of depot medroxyprogesterone acetate (DMPA) for subcutaneous administration (DMPA-SC 104 mg/0.65 ml, Sayana Press) was shown to be as effective as DMPA given by intramuscular administration (DMPA-IM 150 mg/ml, Depo-Provera) for preventing pregnancy. Bone mineral density (BMD) loss and weight gain were similar with both methods (...) of DMPA for subcutaneous administration (DMPA–SC) for use as long-term female contraception, administered every 13 weeks. It is an alternative to DMPA administered by intramuscular injection (DMPA-IM, Depo-Provera) and was launched in the UK in June 2013. DMPA works by inhibiting gonadotrophin secretion, which, in turn, prevents ovulation. This evidence summary is based on 3 trials that evaluated the contraceptive efficacy and safety of DMPA-SC. One of these was a randomised controlled trial

2014 National Institute for Health and Clinical Excellence - Advice

196. Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing (PubMed)

and protein expression, in a tissue- and transporter-dependent manner. Depo-Provera-synchronized mice were dosed vaginally or intraperitoneally with (3)H-TFV, with or without MK571 co-administration, to delineate the function of cervicovaginal Mrp4. Co-administration of MK571 significantly increased the concentration of vaginally-administered TFV in endocervix and vagina. MK571 increased the concentration of intraperitoneally-administered TFV in the cervicovaginal lavage and vagina by several fold

Full Text available with Trip Pro

2016 Biochemical pharmacology

197. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo (PubMed)

against HIV, HSV-2, HPV and unintended pregnancy. Our objective was to evaluate the anti-SHIV-RT activity of MZCL IVR in genital mucosa. First, macaque vaginal tissues were challenged with SHIV-RT in the presence of (i) MIV-150 ± LNG or (ii) vaginal fluids (VF); available from studies completed earlier) collected at various time points post insertion of MZCL and MZC IVRs. Then, (iii) MZCL IVRs (vs. LNG IVRs) were inserted in non-Depo Provera-treated macaques for 24h and VF, genital biopsies, and blood

Full Text available with Trip Pro

2016 PloS one

198. Pathophysiology of Paget's Disease of Bone

NOT have evidence of Paget's disease of bone as defined by: No bone pain or bony deformity Normal serum alkaline phosphatase Exclusion Criteria: Osteosarcoma or other blastic bony metastases alone Fibrous dysplasia of bone Hyperostosis frontalis interna All men and women < 18 years or > 99 years Pregnancy (women) determined by self-report Current use of oral contraceptive tablets or Depo-Provera™ (women) Current use of hormone replacement therapy Creatinine clearance < 60 ml/min./1.73 m2 by Cockcroft

2016 Clinical Trials

199. An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Use of oral contraceptives in the 30 days preceding screening. Use of Depo-Provera® in the preceding 10 months. Use of GnRHas (e.g. Lupron Depot) within 3 months prior to screening (Lupron Depot must have a wash-out period of 3 months prior to screening) Has an IUD in place Current cervical dysplasia classified as Atypical Squamous Cells of Undetermined Significance (ASCUS) associated with high-risk human papilloma virus (HPV) Current diagnosis of Low/High Grade Squamous Intraepithelial Lesion

2016 Clinical Trials

200. Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

bleeding has diabetes has strong family history of breast cancer (defined as one or more first degree relatives, breast cancer occurring before menopause in three or more family members, regardless of degree of relationship, and any male family member with breast cancer), or current or history of breast cancer, or undiagnosed mass detected by breast exam has current or history of cervical cancer has severe cirrhosis (decompensated) or liver tumors has known significant renal disease used Depo-Provera (...) Contraceptive Injection or Depo-subcutaneous Provera 104 (DMPA) products in the past 12 months used any of the following medications within 1 month prior to enrollment: any investigational drug prohibited drugs per protocol oral contraceptives, contraceptive ring or patch levonorgestrel intrauterine system (LNG IUS) or contraceptive implant used a combined injectable contraceptive in the past 6 months less than 3 months since the end of last pregnancy currently lactating is using or plans to use prohibited

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>